Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis

作者：Wang, Zhan; Wang, Zenan; Li, Shu; Li, Binghao; Sun, Lingling; Li, Hengyuan; Lin, Peng; Wang, Shengdong; Teng, Wangsiyuan; Zhou, Xingzhi; Ye, Zhaoming^*

来源：Frontiers in Immunology, 2018, 9: 1239.

DOI：10.3389/fimmu.2018.01239

• decitabine
• osteosarcoma
• gamma delta T cell
• MICB
• UL16-binding protein 1

gamma delta T cell-based immunotherapy for osteosarcoma (OS) has shown limited success thus far. DNA-demethylating agents not only induce tumor cell death but also have an immunomodulatory function. In this study, we have assessed the potential benefit of combining decitabine (DAC, a DNA demethylation drug) and gamma delta T cells for OS immunotherapy. DAC increased the expression of natural killer group 2D (NKG2D) ligands (NKG2DLs), including major histocompatibility complex class I-related chains B (MICB) and UL16-binding protein 1 (ULBP1), on the OS cell surface, making the cells more sensitive to recognition and destruction by cytotoxic gamma delta T cells. The upregulation of MICB and ULBP1 was due to promoter DNA demethylation. Importantly, the killing of OS cells by gamma delta T cells was partially reversed by blocking the NKG2D receptor, suggesting that the gamma delta T cell-mediated cytolysis of DAC-pretreated OS cells was mainly dependent on the NKG2D-NKG2DL axis. The in vivo results were consistent with the in vitro results. In summary, DAC could upregulate MICB and ULBP1 expression in OS cells, and combination treatment involving gamma delta T cell immunotherapy and DAC could be used to enhance the cytotoxic killing of OS cells by gamma delta T cells.

• 出版日期2018-6-1
• 单位浙江大学